Since 2007, Ingram has been a general partner of Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies in the southeast US.
He has also served as an advisor to the CEO of GlaxoSmithKline, since January 2010.
Ingram previously served as vice chairman Pharmaceuticals of GlaxoSmithKline, acting as a special advisor to the Corporate Executive Team and attending its meetings in that capacity, from January 2003 until December 2009.
Prior to that, Ingram was the chief operating officer and president of Pharmaceutical Operations of GlaxoSmithKline from January 2001 to January 2003.
Previously, he was CEO of Glaxo Wellcome from 1997 to 2000 and chairman of Glaxo Wellcome, Glaxo Wellcome plc’s US subsidiary, from 1999 to 2000.
He currently serves on the boards of directors of Allergan, Cree, Edwards Lifesciences Corporation, Lowe’s Companies and Valeant Pharmaceuticals International, where he serves as lead director.
Bob Ingram said he look forward to working with the Board and the management team to deliver long term benefits to science, patients and shareholders.